74‐year‐old male, JAK2‐positive post‐ET MF with splenomegaly and constitutional symptomsRuxolitinib monotherapySome spleen and symptom responseSiramadlin plus ruxolitinib via ADORE (NCT04097821)Multiple SCCs and BCCsCytopenias and lack of splenic/symptom improvementRuxolitinib and navitoclax via REFINE (NCT03222609)Reduced spleen volumeMetastatic Merkel cell carcinoma so unable to continue on trialRuxolitinib monotherapy. This evidence concerns the gene JAK2 and Merkel cell skin cancer.